Recombinant Human Anti-CD28 x Human Anti-CSPG4 Bispecific Antibody (Fv-IgG) (BSDG-H239)

Recombinant Anti-CD28 x Anti-CSPG4 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD28 IgG with similar domains from an anti-CSPG4 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Melanoma therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CSPG4

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Melanoma

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CSPG4

Gene ID

1464

UniProt ID

Q6UVK1

Alternative Names

NG2; Neuron-glial antigen 2; Melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteoglycan 4; CSPG4; MCSP; MCSPG; MSK16; HMW-MAA; MEL-CSPG

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD28 x Human Anti-CSPG4 Bispecific Antibody (Fv-IgG) (BSDG-H239). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD28 x Human Anti-CSPG4 Bispecific Antibody (Fv-IgG) (CAT#: BSDG-H239)

Specifications

Targets

Customer Reviews and Q&As